Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Unlocking Immunotherapy Potential with CapCure: A Novel Chemical Antagonist of PSME4

Ziel

Immunotherapy has transformed cancer treatment, yet many patients fail to benefit because their tumors develop intrinsic mechanisms to block immune attack. Recent discoveries from our ERC-funded work revealed that the proteasome, a central protein degradation system, can be hijacked by tumors to suppress immune recognition and promote an immunosuppressive environment.

This Proof of Concept project aims to translate these findings into a novel therapeutic approach. We will develop and validate small molecules that block this tumor-associated mechanism, restoring the ability of the immune system to detect and eliminate cancer cells. Our focus will be on two major cancers with a high unmet need, non–small cell lung cancer and aggressive breast cancer, where resistance to immunotherapy remains a critical challenge.

The project will combine the development of a small molecule which will allow us to modulate proteasomes activity, together with preclinical validation, and a commercialization pathway including intellectual property protection and market analysis. By the end of the project, we expect to deliver optimized drug candidates and a biomarker-guided framework to identify patients most likely to benefit.

Ultimately, this work seeks to establish a new therapeutic class that enhances the effectiveness of existing immunotherapies, with the long-term goal of improving outcomes for patients whose cancers currently remain resistant to treatment.

Wissenschaftliches Gebiet (EuroSciVoc)

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2026-POC

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

WEIZMANN INSTITUTE OF SCIENCE
Netto-EU-Beitrag
€ 150 000,00
Gesamtkosten
Keine Daten

Begünstigte (1)